Antigen presentation

EQS-News: DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION

Retrieved on: 
Friday, May 3, 2024
Vaccination, DTC, Microsoft Exchange Server, Mouse, OTCQB, Animal, Male, Protein, Unfolded protein response, Female, Disturbance, Antigen presentation, Toxicity, Melanoma, Therapy, Cancer, Vaccine

The use of AccuTOX® to reprogram these MSCs relies mainly on the induction of protein aggregation.

Key Points: 
  • The use of AccuTOX® to reprogram these MSCs relies mainly on the induction of protein aggregation.
  • In addition, our team found that at specific doses, AccuTOX® forms protein aggregates when mixed with tumor lysate, a process that pushes MSCs to degrade these intracellular complexes resulting in potent antigen presentation."
  • The ARM-002TM vaccine is even more potent, as it actually requires 10x less protein.
  • These results will set the target indication for the Phase I trials, and it also shows how versatile and adaptable the ARM-002TM anti-cancer vaccine is.

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

Retrieved on: 
Monday, April 15, 2024
SLATE, Mutation, Safety, HLA, Trial of the century, National Cancer Institute, Vaccine, Gritstone bio, Human, Antigen presentation, BRAF, Oncogene, Patient, TP53, NCI, CTNNB1, Pharmaceutical industry

EMERYVILLE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine. The paper, “A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results,” describes a novel immunodominance hierarchy of tumor neoantigens (including KRAS) that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS, a “pure” KRAS-directed candidate that demonstrated superior immunogenicity to the initial version in a subsequent Phase 2 study and is currently being evaluated in a novel cell therapy-vaccine combination study run by Steven A. Rosenberg of the National Cancer Institute (NCT06253520).

Key Points: 
  • "Our team’s innovative work to develop, optimize and validate SLATE positions Gritstone with two promising platforms to execute against our neoantigen-directed approach to oncology.
  • Neoantigens were identified using Gritstone bio’s proprietary neoantigen prediction platform, EDGETM, and selected based on shared mutation and matched HLA frequencies in patient populations with solid tumors.
  • These data led to the development of SLATE-KRAS, a vaccine focused on KRAS-derived neoantigens that subsequently was evaluated in the Phase 2 portion of the clinical study.
  • Initial Phase 2 data suggesting an increased vaccine induced T cell response were presented in September 2022 ( press release ).

GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target

Retrieved on: 
Wednesday, April 24, 2024
Antigen presentation, AACR, Therapy, Genomics, Merck, IGSF8, NK, Neoplasm, AI, Vaccine

CAMBRIDGE, Mass., April 24, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and cancer biology to create next-generation antibody therapeutics, today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.

Key Points: 
  • CAMBRIDGE, Mass., April 24, 2024 /PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and cancer biology to create next-generation antibody therapeutics, today announced the publication of a peer-reviewed article titled, " IGSF8 is an innate immune checkpoint and cancer immunotherapy target " in the journal Cell.
  • Antigen presentation defects in tumors are prevalent mechanisms of adaptive immune evasion and resistance to cancer immunotherapy, whereas how tumors evade innate immunity is less clear.
  • In this study, the authors discovered that tumors with antigen presentation defects over express IGSF8 which interacts with NK receptors to suppress NK cell cytotoxicity.
  • These results support IGSF8 as a novel innate immune checkpoint that could be exploited as a therapeutic target, and led to the nomination of GV20's lead program, GV20-0251.

EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE

Retrieved on: 
Wednesday, April 10, 2024
Antigen presentation, Neoplasm, Microsoft Exchange Server, DTC, Therapy, Vaccination, Melanoma, OTCQB, Antigen, Vaccine

When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.

Key Points: 
  • When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.
  • Compared to current anti-cancer strategies, vaccination can stimulate specific immune responses capable of potentially curing established tumors.
  • In addition, developed immune cells can lead to a long-lasting memory response capable of further protecting the patient from subsequent cancer relapses.
  • Although the ARMTM vaccine can effectively present antigens to responding T cells, the large amount of antigen preparation required to generate the cellular vaccine might represent challenges in the clinic.

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

Retrieved on: 
Tuesday, April 9, 2024
Antigen presentation, TLS, Survival, Immunotherapy, Patient, Neoplasm, Tumor microenvironment, Observation, Cancer, Doctor of Philosophy, MD, AACR, Therapy, Drug development, Poster, CADL, Pharmaceutical industry

TLSs are ectopic lymphocyte aggregation structures found in the tumor microenvironment and their induction could potentially improve anti-tumor immunity.

Key Points: 
  • TLSs are ectopic lymphocyte aggregation structures found in the tumor microenvironment and their induction could potentially improve anti-tumor immunity.
  • The presentation describes the development of an investigational TLS-inducing multimodal therapeutic using the enLIGHTEN™ Discovery Platform.
  • The enLIGHTEN™ Advanced Analytics suite was applied to immune checkpoint inhibitor-treated patient datasets, and the predicted payload components included factors regulating the development of TLS.
  • “The enLIGHTEN™ Discovery Platform enables the generation of multimodal agents through the integration of artificial intelligence-driven payload combinations into programmable vectors.

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Retrieved on: 
Wednesday, January 24, 2024
Magnetic resonance, Antigen presentation, Patient, Chronic obstructive pulmonary disease, IP, MRI, Inflammatory bowel disease, Pharmacokinetics, Rheumatoid arthritis, Asthma, Fatigue, Joint stiffness, IBD, API, HCQ, Cannabidiol, COPD, Quality of life, Plasma, NDA, FDA, Pain, Lupus erythematosus, Inflammation, Biomarker, Epilepsy, Magnetic resonance imaging, Hydroxychloroquine, Pharmaceutical industry

The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.

Key Points: 
  • The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A.
  • Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options.
  • Overview of Results from Phase 1 Clinical Trial Assessing Tolerability, Safety, and Pharmacokinetics of IHL-675A in Healthy Volunteers
    In 2022 and 2023, Incannex undertook a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of IHL-675A.

Faron Announces Publication of Full Analysis from Phase 1/2 MATINS Trial of Bexmarilimab in Solid Tumors in Cell Reports Medicine

Retrieved on: 
Thursday, December 7, 2023
Immunotherapy, Survival, Immune system, Principal, PD-1, Nasdaq First North, AIM, Neoplasm, Faron Pharmaceuticals, Patient, Safety, Antigen presentation, Macrophage

TURKU, Finland and BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage reprogramming for effective anticancer immunotherapies, today announces the publication of the full safety and anti-tumor efficacy results from the first-in-human Phase 1/2 MATINS trial of bexmarilimab in patients with treatment-refractory late-stage solid tumors in Cell Reports Medicine.

Key Points: 
  • TURKU, Finland and BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage reprogramming for effective anticancer immunotherapies, today announces the publication of the full safety and anti-tumor efficacy results from the first-in-human Phase 1/2 MATINS trial of bexmarilimab in patients with treatment-refractory late-stage solid tumors in Cell Reports Medicine.
  • The publication, entitled, “Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial” is available online at Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial: Cell Reports Medicine
    “Positive Phase 1/2 data published in Cell Reports Medicine highlights bexmarilimab’s potential to overcome cancer immune resistance by restoring macrophage immune function,” said Petri Bono, MD, PhD., Chief Medical Officer, Terveystalo Finland and Principal Investigator of the MATINS study.
  • "We are pleased to see that bexmarilimab was safe and very well-tolerated, achieving disease control and prolonged survival in a proportion of patients with very late-stage solid tumors who have exhausted all standard treatment options.
  • The Phase 1/2 first-in-human MATINS trial evaluated the safety and efficacy of CLEVER-1 blockade with bexmarilimab in patients with treatment-refractory solid tumors.

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Retrieved on: 
Monday, November 27, 2023
Christian democracy, Family, PDC, Antigen, B cell, Immunology, BDCA2, IND, Autoimmunity, Research, Plasma cell, SLE, Inflammation, Half-life, CD122, SAN, Lupus, GMP, CNTA, Monocyte, Patient, Antigen presentation, Therapy, Vaccine

Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.

Key Points: 
  • Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.
  • Under the terms of the agreement, Anaptys will receive from Centessa Pharmaceuticals an exclusive, global license for ANB101.
  • Anaptys will also receive the same rights to ANB102, an extended half-life BDCA2 modulator with the potential to enable quarterly or less frequent dosing.
  • Centessa is eligible to receive an additional development milestone payment and low single-digit royalties on global net sales.

Faron Reports Half-Year Financial Results, January 1 – June 30, 2023

Retrieved on: 
Tuesday, August 29, 2023
Faron Pharmaceuticals, MCR, Survival, HMA, Bone marrow, Head, MBA, Congress, Nasdaq First North, Patient, MedRxiv, Majesty of the Seas, Executive, AIM, European Hematology Association, NK, Manuscript, Celgene, ORS, PD-1, FDA, IPF, Venetoclax, ODD, Cancer, American Association for Cancer Research, Immunotherapy, Antigen presentation, Biomarker, CR, Tuomo, Bristol Myers Squibb, MDS, EUR, AML, Azacitidine, CPA, Tumor microenvironment, Lithium, Pharmaceutical industry, Vaccine, Management, Security (finance), Rare-earth element, Medical imaging, Fårö, Phase, SOC

TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces unaudited half-year financial results for January 1 to June 30, 2023 (the "period").

Key Points: 
  • Mr. Leopoldo Zambeletti stepped down from the Board to assume a business development consulting role at Faron.
  • TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces unaudited half-year financial results for January 1 to June 30, 2023 (the "period").
  • "I am extremely proud of the progress we made in the first half of 2023,” said Dr. Markku Jalkanen, Chief Executive Officer of Faron.
  • On June 30, 2023, the Company had outstanding borrowings of EUR 9.8 million under a loan facility with IPF Partners which is subject to financial covenants.

Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes

Retrieved on: 
Monday, June 26, 2023
IU, JDRF, Indiana University, University, Therapy, Diabetes, MSN, Polyamine, Survival, PBLA, Research, Cell, RNA, Doctor of Philosophy, Proteomics, Incidence, Indiana University School of Medicine, Patient, Antigen presentation, ODC, Reactive oxygen species, DFMO, School, Endocrine Society, Mouse, Poster, Ornithine decarboxylase, Pharmaceutical industry, Vaccine, T1D, Eflornithine, Medicine

The research is part of a multi-site clinical trial led by Indiana University School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.

Key Points: 
  • The research is part of a multi-site clinical trial led by Indiana University School of Medicine, supported by funding from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization.
  • Panbela Therapeutics is providing the drug at no cost to researchers and was not involved in the design and analysis of these studies.
  • In the Phase 1 dose range finding study of in patients with recent onset T1D, CPP-1X was well tolerated and a dose dependent inhibition of ODC was observed.
  • Results from these studies suggest that CPP-1X is a safe, oral treatment option that may improve β cell function and/or survival in recent onset T1D.